AIMS: This study assessed survival, morbidity and impact of pacemaker (PM) therapy in children with Congenital Complete Atrioventricular Block (CCAVB). METHODS AND RESULTS: Data of 32 children, diagnosed as showing CCAVB at a median age of 0.4 years (range foetal-10 years), were retrospectively analysed. For comparison of clinical data patients were separated into two groups: CCAVB without structural heart disease (group 1; n = 23) and with structural heart disease (group 2; n = 9). Median follow-up time was 10.2 years. Pacemakers (PM) were implanted in 17 group 1 and all group 2 children. Frequency of PM therapy, age and symptoms before PM implantation did not differ significantly between the groups. Indications for PM implantation were bradycardia in 15, decreased exercise tolerance in 6, syncope in 3 and heart failure in 2 children. PM system related complications occurred in 11/26 (42%) children. Although 1 child died due to PM exit block no further CCAVB related symptoms were recorded in children with PM. CONCLUSION: PM therapy reduces mortality and morbidity in children with CCAVB when compared with natural history data. Although children with PM are free from CCAVB related symptoms limited morbidity remains due to PM system related complications.
AIMS: This study assessed survival, morbidity and impact of pacemaker (PM) therapy in children with Congenital Complete Atrioventricular Block (CCAVB). METHODS AND RESULTS: Data of 32 children, diagnosed as showing CCAVB at a median age of 0.4 years (range foetal-10 years), were retrospectively analysed. For comparison of clinical data patients were separated into two groups: CCAVB without structural heart disease (group 1; n = 23) and with structural heart disease (group 2; n = 9). Median follow-up time was 10.2 years. Pacemakers (PM) were implanted in 17 group 1 and all group 2 children. Frequency of PM therapy, age and symptoms before PM implantation did not differ significantly between the groups. Indications for PM implantation were bradycardia in 15, decreased exercise tolerance in 6, syncope in 3 and heart failure in 2 children. PM system related complications occurred in 11/26 (42%) children. Although 1 child died due to PM exit block no further CCAVB related symptoms were recorded in children with PM. CONCLUSION: PM therapy reduces mortality and morbidity in children with CCAVB when compared with natural history data. Although children with PM are free from CCAVB related symptoms limited morbidity remains due to PM system related complications.
Authors: Christopher John McLeod; Christine H Attenhofer Jost; Carole A Warnes; David Hodge; Linda Hyberger; Heidi M Connolly; Samuel J Asirvatham; Joseph A Dearani; David L Hayes; Naser M Ammash Journal: J Interv Card Electrophysiol Date: 2010-06-19 Impact factor: 1.900
Authors: Helena M Gardiner; Cristian Belmar; Lucia Pasquini; Anna Seale; Matthew Thomas; William Dennes; Myles J O Taylor; Elena Kulinskaya; Ruwan Wimalasundera Journal: Heart Date: 2006-11-03 Impact factor: 5.994
Authors: Roberto Márcio de Oliveira Júnior; Kátia Regina da Silva; Tatiana Satie Kawauchi; Lucas Bassolli de Oliveira Alves; Elizabeth Sartori Crevelari; Martino Martinelli Filho; Roberto Costa Journal: Arq Bras Cardiol Date: 2014-11-11 Impact factor: 2.000